ASX Release

MALARIA TRIAL - PATIENT DOSING COMMENCED

Highlight:

- Patient dosing with ArTiMist™, of the first of the 150 paediatric patients in pivotal. open-label randomised, Confirmatory Trial has commenced in Rwanda

Eastland Medical Systems Ltd (ASX:EMS) today announces that Dr Stephen Rulisa the principal investigator has confirmed that treatment dosing of the first of its 150 paediatric patients in its Confirmatory Trial for our sublingual malaria treatment ArTiMist™ has commenced in Rwanda.

Rwanda is the first of 4 sites in Africa that will be participating in the randomised, comparative open-label trial, enrolling children up to the age of 5 with severe or complicated *P. falciparum* malaria, or uncomplicated *P. falciparum* malaria with gastrointestinal complications.

The primary objective is to demonstrate the superiority of the sublingual ArTiMist™ treatment when compared to Intravenous quinine, which is recommended by the WHO in its current treatment guidelines.

"The commercial value of our new ArTiMist™ sublingual malaria treatment continues to increase as we successfully execute each element of our development programme", said Stephen Carter, CEO of Eastland. "We anticipate completing the trial on schedule and in parallel we will continue to identify and engage with prospective partners. We are excited about the prospect of seeing this unique treatment being made available to patients and in doing so, delivering strong financial returns back to Eastland and its many investors", he said.

Background; Feedback from the earlier Rwandan Phase 2a trial subjects and physicians, including Dr Rulisa, on the use of the new sublingual malaria treatment has been very positive and the rate of compliance and acceptance with the treatment has been very high.

Recently, Eastland published results from its Phase 2a trial, at the IAAC conference in Boston, USA which further gained international partnering interest in the project. Eastland and AFG Venture group continue to identify and evaluate potential partners.

Further information:
Stephen Carter
CEO
Eastland Medical Systems Ltd
t: +61 8 6142 5555
sjcarter@eastlandmedical.com.au

Highlights

- **Positive results achieved from Phase I multi and single dose clinical studies for ArTiMist™ indicating the formulation was well tolerated and showed no adverse effects in any of the study subjects.**
- **ArTiMist™ Phase IIa Clinical Field Trial completed in February 2010 in Rwanda.**
- **Very positive successful results achieved from Phase IIa ArTiMist™ trial.**